TrialClinical and translational science2017

A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.

M Levisetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.